X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs SUN PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD SUN PHARMA BIOCON LTD/
SUN PHARMA
 
P/E (TTM) x 92.6 38.0 243.4% View Chart
P/BV x 7.8 4.2 186.0% View Chart
Dividend Yield % 0.1 0.5 27.1%  

Financials

 BIOCON LTD   SUN PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
SUN PHARMA
Mar-17
BIOCON LTD/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,188842 141.1%   
Low Rs305572 53.3%   
Sales per share (Unadj.) Rs68.7131.6 52.2%  
Earnings per share (Unadj.) Rs7.632.7 23.1%  
Cash flow per share (Unadj.) Rs14.038.0 36.8%  
Dividends per share (Unadj.) Rs1.003.50 28.6%  
Dividend yield (eoy) %0.10.5 27.1%  
Book value per share (Unadj.) Rs86.3152.7 56.5%  
Shares outstanding (eoy) m600.002,399.26 25.0%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.95.4 202.1%   
Avg P/E ratio x98.921.6 457.1%  
P/CF ratio (eoy) x53.418.6 286.9%  
Price / Book Value ratio x8.64.6 186.7%  
Dividend payout %13.210.7 123.7%   
Avg Mkt Cap Rs m447,9001,696,877 26.4%   
No. of employees `0006.117.5 35.1%   
Total wages/salary Rs m9,31149,023 19.0%   
Avg. sales/employee Rs Th6,705.818,028.3 37.2%   
Avg. wages/employee Rs Th1,514.22,798.8 54.1%   
Avg. net profit/employee Rs Th736.94,479.5 16.4%   
INCOME DATA
Net Sales Rs m41,234315,784 13.1%  
Other income Rs m2,0626,232 33.1%   
Total revenues Rs m43,296322,016 13.4%   
Gross profit Rs m8,291100,893 8.2%  
Depreciation Rs m3,85112,648 30.4%   
Interest Rs m6153,998 15.4%   
Profit before tax Rs m5,88790,479 6.5%   
Minority Interest Rs m2130-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,56912,116 13.0%   
Profit after tax Rs m4,53178,462 5.8%  
Gross profit margin %20.131.9 62.9%  
Effective tax rate %26.713.4 199.0%   
Net profit margin %11.024.8 44.2%  
BALANCE SHEET DATA
Current assets Rs m41,486329,537 12.6%   
Current liabilities Rs m21,413178,870 12.0%   
Net working cap to sales %48.747.7 102.0%  
Current ratio x1.91.8 105.2%  
Inventory Days Days6479 81.0%  
Debtors Days Days9483 113.1%  
Net fixed assets Rs m50,661204,766 24.7%   
Share capital Rs m3,0002,399 125.0%   
"Free" reserves Rs m48,808363,997 13.4%   
Net worth Rs m51,808366,397 14.1%   
Long term debt Rs m17,89814,361 124.6%   
Total assets Rs m99,897614,102 16.3%  
Interest coverage x10.623.6 44.7%   
Debt to equity ratio x0.30 881.4%  
Sales to assets ratio x0.40.5 80.3%   
Return on assets %5.213.4 38.4%  
Return on equity %8.721.4 40.8%  
Return on capital %9.624.8 38.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05844,118 27.3%   
Fx outflow Rs m7,34824,484 30.0%   
Net fx Rs m4,71019,634 24.0%   
CASH FLOW
From Operations Rs m6,62170,822 9.3%  
From Investments Rs m-6,840-42,216 16.2%  
From Financial Activity Rs m-2,397-22,854 10.5%  
Net Cashflow Rs m-2,6126,107 -42.8%  

Share Holding

Indian Promoters % 40.4 63.7 63.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 5.1 163.7%  
FIIs % 10.7 23.0 46.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 8.3 239.8%  
Shareholders   109,995 133,026 82.7%  
Pledged promoter(s) holding % 0.0 0.5 7.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   DR. DATSONS LABS  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Sep 18, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS